基于CCL2/CCR2信号轴的肿瘤免疫治疗药物的研究进展OA北大核心CSTPCD
Research progress of drugs for cancer immunotherapy based on CCL2/CCR2 signaling axis
趋化因子配体2(C-C motif chemokine ligand 2,CCL2)及其受体CCR2与肿瘤的发生、发展密切相关.CCL2/CCR2信号轴通过多种机制促进肿瘤进展,一方面CCL2与肿瘤细胞表面的CCR2结合促进肿瘤的生长/存活和转移;更为重要的是CCL2可以招募多种免疫抑制细胞在肿瘤微环境中聚集,抑制免疫细胞的功能和活性,促进肿瘤进展.本文综述了CCL2/CCR2信号轴以及其在肿瘤及肿瘤微环境中的作用,并重点介绍了靶向CCL2/CCR2信号轴药物的临床研究进展,以期深入并全面了解CCL2/CCR2信号轴在肿瘤进展中的作用机制,开发更有效的肿瘤免疫治疗药物.
C-C motif chemokine ligand 2(CCL2)and its receptor CCR2 are closely related to tumorigenesis and tumor progression.The CCL2/CCR2 signaling axis promotes tumor progression through multiple mechanisms:CCL2 binds to CCR2 on the surface of tumor cells,and thus promotes tumor growth/survival and metastasis;more importantly,CCL2 recruits a variety of immunosuppressive cells to aggregate in the tumor microenvironment,and inhibits the function and activity of immune cells,promoting tumor progression.The article reviews the CCL2/CCR2 signaling axis and its role in tumors and tumor microenvironment,with particular focus on the advances in clinical research on drugs targeting CCL2/CCR2 signaling axis,in order to gain an in-depth and overall understanding of the mechanism of action of CCL2/CCR2 axis in tumor progression and develop more effective anti-tumor immunotherapeutic agents.
崔珍珍;赵一凡;孙玉;孟佳怡;康迪;胡立宏
南京中医药大学药学院, 江苏省中药功效物质重点实验室, 南京 210023
药学
CCL2CCR2肿瘤免疫治疗肿瘤微环境免疫抑制细胞
CCL2CCR2cancer immunotherapytumor microenvironmentimmunosuppressive cells
《中国药科大学学报》 2024 (001)
WSTF-RPB1介导的急性髓细胞白血病靶向治疗耐药的分子机制及治疗策略研究
36-44 / 9
This work was supported by the National Natural Science Foundation of China(No.82104270)and the Graduate Research and Innovation Projects of Jiangsu Province(KYCX22_2035)国家自然科学基金项目(No.82104270);江苏省研究生实践创新计划项目(KYCX22_2035)
评论